WO2009124056A3 - Alpha-fetoprotein for treating disease - Google Patents

Alpha-fetoprotein for treating disease Download PDF

Info

Publication number
WO2009124056A3
WO2009124056A3 PCT/US2009/038964 US2009038964W WO2009124056A3 WO 2009124056 A3 WO2009124056 A3 WO 2009124056A3 US 2009038964 W US2009038964 W US 2009038964W WO 2009124056 A3 WO2009124056 A3 WO 2009124056A3
Authority
WO
WIPO (PCT)
Prior art keywords
fetoprotein
alpha
treating disease
afp
mammal
Prior art date
Application number
PCT/US2009/038964
Other languages
French (fr)
Other versions
WO2009124056A2 (en
Inventor
Robert Mulroy
Edward J. Stewart
James Murray
Original Assignee
Merrimack Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.
Publication of WO2009124056A2 publication Critical patent/WO2009124056A2/en
Publication of WO2009124056A3 publication Critical patent/WO2009124056A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed are methods of treating psoriatic arthritis, IgA nephropathy, Hashimoto's disease, Sjogren's syndrome, ankylosing spondylitis, and uveitis in a mammal, involving administering to the mammal a therapeutically effective amount of an alpha-fetoprotein (AFP) or a biologically active fragment, derivative, or analog thereof. Compositions and kits containing an AFP or biologically active fragment, derivative, or analog thereof are also disclosed.
PCT/US2009/038964 2008-04-01 2009-03-31 Alpha-fetoprotein for treating disease WO2009124056A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4148908P 2008-04-01 2008-04-01
US61/041,489 2008-04-01

Publications (2)

Publication Number Publication Date
WO2009124056A2 WO2009124056A2 (en) 2009-10-08
WO2009124056A3 true WO2009124056A3 (en) 2010-06-17

Family

ID=41136090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/038964 WO2009124056A2 (en) 2008-04-01 2009-03-31 Alpha-fetoprotein for treating disease

Country Status (1)

Country Link
WO (1) WO2009124056A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013001819A1 (en) * 2011-06-30 2015-02-23 株式会社 免疫生物研究所 Soluble integrin α4 mutant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070169211A1 (en) * 2000-01-06 2007-07-19 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US20070253973A1 (en) * 2006-03-30 2007-11-01 Cogenesys, Inc. Fusion proteins comprising alpha fetoprotein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070169211A1 (en) * 2000-01-06 2007-07-19 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US20070253973A1 (en) * 2006-03-30 2007-11-01 Cogenesys, Inc. Fusion proteins comprising alpha fetoprotein

Also Published As

Publication number Publication date
WO2009124056A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
WO2006060314A3 (en) Generation of replication competent viruses for therapeutic use
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
WO2011106573A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
EP2687220A3 (en) Treatment of inflammatory diseases using placental stem cells
WO2010022177A3 (en) Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NO20091501L (en) Pharmaceutical compositions
TR201903008T4 (en) Compositions suitable for treating collagen-mediated diseases.
DE502006006107D1 (en) AMID SUBSTITUTED 8-N-BENZIMIDAZOLE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
ATE479433T1 (en) NEW LONG-ACTING BETA-2 AGONISTS AND THEIR USE AS MEDICINAL PRODUCTS
WO2009044392A3 (en) Novel sirna structures
IN2015DN01786A (en)
TW200833840A (en) Toxin peptide therapeutic agents
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
CL2007003690A1 (en) COMPOUNDS DERIVED FROM 1-AZONIA-BICICLO [2.2.2] OCTANO; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES.
NZ578928A (en) Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases
RS55012B1 (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, process for their production and their use as anti-inflammatory agents
WO2005121778A3 (en) Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2005095652A3 (en) Pnmt as a novel marker for progenitor cells
WO2011038933A3 (en) Anti-hsv antibody
CL2008001393A1 (en) Compounds derived from dihydroquinones and dihydronaphthyridines, jnk inhibitors; pharmaceutical composition comprising said compounds; and its use to treat rheumatoid arthritis, asthma, type 2 diabetes, Alzheimer's, Parkinson's disease, cell hyperproliferation.
WO2006096529A3 (en) Genes involved in neurodegenerative conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09728019

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009728019

Country of ref document: EP